News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,000 Results
Type
Article (14682)
Company Profile (111)
Press Release (270198)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (90760)
Career Advice (465)
Deals (15923)
Drug Delivery (73)
Drug Development (38969)
Employer Resources (51)
FDA (6576)
Job Trends (6384)
News (155857)
Policy (14486)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (13)
Adcomms (8)
Allergies (68)
Alliances (23965)
ALS (74)
Alzheimer's disease (666)
Antibody-drug conjugate (ADC) (103)
Approvals (6768)
Artificial intelligence (213)
Autoimmune disease (42)
Automation (13)
Bankruptcy (151)
Best Places to Work (4520)
BIOSECURE Act (9)
Biosimilars (119)
Biotechnology (44)
Bladder cancer (38)
Brain cancer (36)
Breast cancer (194)
Cancer (1436)
Cardiovascular disease (153)
Career advice (418)
Career pathing (13)
CAR-T (59)
CDC (6)
Cell therapy (173)
Cervical cancer (9)
Clinical research (33954)
Collaboration (763)
Compensation (358)
Complete response letters (34)
COVID-19 (805)
CRISPR (46)
C-suite (448)
Cystic fibrosis (59)
Data (2075)
Denatured (18)
Depression (62)
Diabetes (132)
Diagnostics (1439)
Digital health (8)
Diversity (3)
Diversity, equity & inclusion (14)
Drug discovery (118)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (90)
Earnings (34719)
Editorial (21)
Employer branding (4)
Employer resources (46)
Events (41707)
Executive appointments (547)
FDA (7758)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (465)
Gene editing (75)
Generative AI (19)
Gene therapy (200)
GLP-1 (446)
Government (1433)
Grass and pollen (4)
Guidances (168)
Healthcare (3943)
HIV (11)
Huntington's disease (12)
IgA nephropathy (37)
Immunology and inflammation (74)
Immuno-oncology (15)
Indications (56)
Infectious disease (872)
Inflammatory bowel disease (78)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (119)
Interviews (60)
IPO (6264)
IRA (33)
Job creations (2077)
Job search strategy (374)
JPM (30)
Kidney cancer (9)
Labor market (28)
Layoffs (211)
Leadership (8)
Legal (3491)
Liver cancer (22)
Longevity (8)
Lung cancer (219)
Lymphoma (129)
Machine learning (15)
Management (18)
Manufacturing (416)
MASH (68)
Medical device (1390)
Medtech (1397)
Mergers & acquisitions (10106)
Metabolic disorders (452)
Multiple sclerosis (74)
NASH (14)
Neurodegenerative disease (121)
Neuropsychiatric disorders (54)
Neuroscience (1246)
Neurotech (1)
NextGen: Class of 2026 (1687)
Non-profit (640)
Now hiring (17)
Obesity (238)
Opinion (148)
Ovarian cancer (39)
Pain (111)
Pancreatic cancer (54)
Parkinson's disease (120)
Partnered (11)
Patents (243)
Patient recruitment (135)
Peanut (12)
People (30348)
Pharmaceutical (65)
Pharmacy benefit managers (18)
Phase 1 (9056)
Phase 2 (14494)
Phase 3 (12691)
Pipeline (2084)
Policy (135)
Postmarket research (1434)
Preclinical (3665)
Press Release (26)
Prostate cancer (84)
Psychedelics (24)
Radiopharmaceuticals (141)
Rare diseases (382)
Real estate (2735)
Recruiting (18)
Regulatory (11343)
Reports (15)
Research institute (606)
Resumes & cover letters (55)
Rett syndrome (13)
RNA editing (7)
RSV (21)
Schizophrenia (87)
Series A (86)
Series B (57)
Service/supplier (2)
Sickle cell disease (48)
Special edition (10)
Spinal muscular atrophy (92)
Sponsored (13)
Startups (1696)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (69)
The Weekly (45)
Vaccines (236)
Venture capital (33)
Weight loss (142)
Women's health (27)
Worklife (4)
Date
Last 7 days (188)
Last 30 days (708)
Last 365 days (11321)
2026 (1026)
2025 (11634)
2024 (13527)
2023 (15386)
2022 (20739)
2021 (21280)
2020 (19926)
2019 (15811)
2018 (12313)
2017 (14344)
2016 (13554)
2015 (15981)
2014 (12777)
2013 (10834)
2012 (11635)
2011 (12167)
2010 (11088)
Location
Africa (321)
Alabama (22)
Alaska (1)
Arizona (79)
Arkansas (3)
Asia (21647)
Australia (2833)
California (3445)
Canada (1514)
China (594)
Colorado (146)
Connecticut (135)
Delaware (129)
Europe (42241)
Florida (691)
Georgia (68)
Hawaii (1)
Idaho (12)
Illinois (359)
India (44)
Indiana (251)
Iowa (2)
Japan (255)
Kansas (77)
Kentucky (21)
Louisiana (5)
Maine (2)
Maryland (460)
Massachusetts (2960)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (9)
Nebraska (7)
Nevada (18)
New Hampshire (8)
New Jersey (1479)
New Mexico (8)
New York (1156)
North Carolina (633)
North Dakota (3)
Northern California (1574)
Ohio (85)
Oklahoma (6)
Oregon (19)
Pennsylvania (766)
Puerto Rico (12)
Rhode Island (18)
South America (513)
South Carolina (10)
Southern California (1500)
Tennessee (53)
Texas (539)
United States (13972)
Utah (61)
Virginia (161)
Washington D.C. (42)
Washington State (243)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
285,000 Results for "cns pharmaceuticals inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CNS Pharmaceuticals Issues Letter to Shareholders - January 27, 2026
January 28, 2026
·
7 min read
Press Releases
CNS Pharmaceuticals Announces CEO Transition
December 17, 2025
·
5 min read
Press Releases
Sysmex America Expands CN™-Series with CN-9000 to Help Labs of All Sizes Optimize Workflow
January 22, 2026
·
2 min read
Press Releases
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.
December 4, 2025
·
1 min read
Press Releases
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
December 4, 2025
·
4 min read
Press Releases
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
November 24, 2025
·
2 min read
Press Releases
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 18, 2025
·
5 min read
Press Releases
Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
December 11, 2025
·
4 min read
Press Releases
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
November 11, 2025
·
2 min read
Press Releases
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
November 24, 2025
·
6 min read
1 of 28,500
Next
